Cargando…
Fuzuloparib: First Approval
Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380563/ https://www.ncbi.nlm.nih.gov/pubmed/34118019 http://dx.doi.org/10.1007/s40265-021-01541-x |
_version_ | 1783741221617795072 |
---|---|
author | Lee, Arnold |
author_facet | Lee, Arnold |
author_sort | Lee, Arnold |
collection | PubMed |
description | Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs. This article summarizes the milestones in the development of fuzuloparib leading to this first approval for the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer in patients with germline BRCA mutation who have undergone second-line or above chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-021-01541-x. |
format | Online Article Text |
id | pubmed-8380563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83805632021-09-08 Fuzuloparib: First Approval Lee, Arnold Drugs AdisInsight Report Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs. This article summarizes the milestones in the development of fuzuloparib leading to this first approval for the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer in patients with germline BRCA mutation who have undergone second-line or above chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-021-01541-x. Springer International Publishing 2021-06-12 2021 /pmc/articles/PMC8380563/ /pubmed/34118019 http://dx.doi.org/10.1007/s40265-021-01541-x Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | AdisInsight Report Lee, Arnold Fuzuloparib: First Approval |
title | Fuzuloparib: First Approval |
title_full | Fuzuloparib: First Approval |
title_fullStr | Fuzuloparib: First Approval |
title_full_unstemmed | Fuzuloparib: First Approval |
title_short | Fuzuloparib: First Approval |
title_sort | fuzuloparib: first approval |
topic | AdisInsight Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380563/ https://www.ncbi.nlm.nih.gov/pubmed/34118019 http://dx.doi.org/10.1007/s40265-021-01541-x |
work_keys_str_mv | AT leearnold fuzuloparibfirstapproval |